These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
857 related articles for article (PubMed ID: 18061248)
1. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248 [TBL] [Abstract][Full Text] [Related]
2. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334 [TBL] [Abstract][Full Text] [Related]
3. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939 [TBL] [Abstract][Full Text] [Related]
4. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702 [TBL] [Abstract][Full Text] [Related]
5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Park Y; Lee JH; Hong DJ; Lee EY; Kim HS Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107 [TBL] [Abstract][Full Text] [Related]
7. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Azzam AZ; Hashad DI; Kamel NA Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457 [TBL] [Abstract][Full Text] [Related]
9. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622 [TBL] [Abstract][Full Text] [Related]
10. Test of ovarian cancer multiplex xMAP technology panel. Vrzalova J; Prazakova M; Novotny Z; Topolcan O; Casova M; Holubec L Anticancer Res; 2009 Feb; 29(2):573-6. PubMed ID: 19331205 [TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
12. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Holcomb K; Vucetic Z; Miller MC; Knapp RC Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856 [TBL] [Abstract][Full Text] [Related]
14. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277 [TBL] [Abstract][Full Text] [Related]
15. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475 [TBL] [Abstract][Full Text] [Related]
17. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
19. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682 [TBL] [Abstract][Full Text] [Related]
20. Validation of serum biomarkers for detection of early-stage ovarian cancer. Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]